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Abstract  
 
Objective 
Documentations of the experiences of patients with advanced prostate cancer and 
their partners are sparse. Views of care and treatment received for metastatic 
castrate resistant prostate cancer (mCRPC) are presented here. 
 
Methods 
Structured interviews conducted within 14 days of a systemic therapy for mCRPC 
starting and 3 months later explored: treatment decisions, information provision, 
perceived benefits and harms of treatment, and effects of these on patients’ and 
partners’ lives. 
 
Results 
Thirty-seven patients and 33 partners recruited from UK cancer centres participated. 
The majority of patients (46%) reported pain was their worst symptom and many 
wanted to discuss its management (baseline-50%; 3 months-33%). Patients and 
partners believed treatment would: delay progression (>75%), improve wellbeing 
(33%), alleviate pain (≈12%) and extend life (15% -patients, 36% -partners). At 3 
months most men (42%) said fatigue was the worst treatment-related side effect 
(SE), 27% experienced unexpected SEs, and 54% needed help with SEs. Most 
patients received SE information (85% written; 75% verbally); many additionally 
searched the internet (33%-patients; 55%-partners). Only 54% of patients said nurse 
support was accessible.  
 
Conclusion 
Pain and other symptom management is not optimal. Increased specialist nurse 
provision and earlier palliative care links are needed. Dedicated clinics may be 
justified. 
 
 
Keywords 
Advanced prostate cancer; interviews; supportive care 
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Introduction  
For men who present with, or progress to, advanced (metastatic) prostate cancer the 
mainstay of treatment is Androgen Deprivation Therapy (ADT) alone or in 
combination with docetaxel chemotherapy [Sweeney et al, 2015; James et al, 2016; 
Cornford et al, 2017; Morris et al, 2018]. Unfortunately the development of resistance 
to ADT is inevitable in most cases [Debres & Tindall, 2004] and is known as 
metastatic castrate resistant prostate cancer (mCRPC).  Adding therapies 
sequentially to ADT such as first-line, second-line, or re-challenge with 
chemotherapy (docetaxel and cabazitaxel) [Petrylak et al, 2004; Tannock et al, 2004; 
De Bono et al, 2010] or bone targeted agents (Radium -223) [Parker et al, 2013)] 
have demonstrated gains in overall survival (OS). Moreover, the last decade has 
seen the understanding of castrate resistance change; it is not uniform and has 
multiple underlying pathways [Karantanos et al, 2015]. In some cases control of 
disease progression is possible by hormonal manipulation with drugs such as 
abiraterone acetate (androgen biosynthesis inhibitor) and enzalutamide 
(antiandrogen). Both have demonstrated significant advantages for OS, progression 
free survival (PFS) and quality of life (QoL) in the pre and post docetaxel settings 
[Nuhn et al, 2018]. The exact sequencing of these further therapies for any individual 
man remains uncertain. Factors influencing this include: - heterogeneity of the 
prostate cancer and tumour factors such as Gleason Grade, PSA kinetics, the sites 
of recurrence (visceral, bone or nodal), patient co-morbidities, potential toxicities of 
drugs, and importantly patient choice depending on an individual’s circumstances. 
Also of note is a current lack of sufficiently robust biomarkers that predict response 
or toxicity/tolerability of any individual treatment [Armstrong 2017].  
 
This is a complex backdrop for treatment decision making and not surprisingly the 
management of mCRPC requires a multidisciplinary team (MDT) approach. For the 
process to be truly patient centred, men with mCRPC need to receive information 
and counselling about all of the available therapy options at each stage of their 
disease. Different and multiple specialties will be providing information which makes 
it essential that MDT members are aware of each other’s roles so that patients 
receive accurate and consistent information to guide treatment decisions. The 
American Society of Clinical Oncology (ASCO) guidelines for survivors of prostate 
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cancer recommend that an individual’s information needs at all stages of disease are 
assessed and patients provided with or referred to the appropriate sources for 
information and support [Resnick et al, 2015]. The little evidence that exists shows a 
shortfall in services provision [Jenkins & Fallowfield, 2016]. Three studies from 
Canada [Carter et al, 2010; Carter et al, 2011; Carter et al, 2014] with men most of 
whom had castrate resistant disease, their partners, and health professionals found 
information provision was less than optimal for key topics such as treatments and 
associated side effects (SE), progression of disease and available supportive care 
services. Many patients did not understand the treatment information, especially how 
treatments worked, and had difficulty getting answers to questions; equally worrying 
oncologists and specialist nurses acknowledged an awareness of these 
shortcomings. A qualitative study of Australian men diagnosed with advanced 
prostate cancer [Chambers et al, 2018] also identified difficulties with accessible 
informational support about the disease and treatment. The study revealed that the 
partner was the catalyst for seeking information and getting help from the supportive 
services and that they needed to be involved and supported too. The influence of 
factors such as age, expression of masculinities and models of coping with illness 
also emerged which has implications for the design of care models. Our own recent 
UK clinician survey showed men with mCRPC are managed mostly in general 
urological oncology clinics where the mix and level of staffing is not ideal for 
focussing on their complex needs [Jenkins et al, 2018a]. Minimal availability of 
specialist nursing and palliative care staff created a situation where achieving 
optimal QoL for patients was challenging. Similar to the Canadian findings, important 
topics such as prognosis, SE amelioration, patient’s current goals and access to 
supportive care were frequently identified by the UK clinicians as omissions, in what 
were time restrained consultations with patients. This suggests more evidence based 
research into meeting the specific needs of men with mCRPC and their families is 
required. 
 
As part of a UK prospective study examining the EXperiences, TREatments and 
Quality Of Life (EXTREQOL) in men diagnosed with mCRPC structured interviews 
were conducted with patients and their partners. This was to explore experiences of 
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treatment decisions, information provision, perceived benefits and harms of 
treatment and the effects of these on their lives; the findings are presented here. 
 
Methods  
A prospective longitudinal mixed-methods observational design was used in 
EXTREQOL and included structured interviews with patients and their partners.  
Twenty hospitals in 19 Trusts in England, Scotland and Wales provided access to 
men considered suitable for systemic treatment for mCRPC between July 2016 and 
July 2017. Exclusion criteria were not having a diagnosis of mCRPC, those with 
current or historical anxiety and/or depression or psychiatric illness. Ethical approval 
(16/LO/0403) was granted by the London-Surrey Boarder Research Ethics 
Committee and sponsorship and all local NHS R&D permissions were obtained for 
the study.  
 
Procedures 
Eligible patients were identified and initially approached by a member of the clinical 
team who briefly explained the study together with providing the Information Sheet. 
Neither being interviewed, nor having a partner willing to be interviewed, was a pre-
requisite of the study, but it was made clear that there was opportunity for this within 
the study. Interested patients completed an expression of interest form with their 
contact details and gave permission for researchers to phone them no sooner than 
24 hours later to discuss the study. Written informed consent was obtained prior to 
participation. Consecutive sampling was used with a pragmatic target of interviewing 
30 men and if applicable their partners. 
 
Interviews 
Taking into account preference, interviews took place either in-person at home, or by 
telephone and were carried out within 14 days of a systemic therapy [any line] being 
initiated for mCRPC, and after 3 months of treatment. Patient and partner interviews 
were conducted independently of each other, were undertaken by three researchers 
(SC, VJ, LM) experienced in interviewing and lasted between 15-45 minutes. The 
interview schedules, four in total (patient baseline & 3 months and partner baseline & 
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3 months), were developed and piloted. Patient demography was collected and 
questions asked about treatment history, experiences of treatment decisions, 
symptoms (particularly pain) and related side effects, information provision, 
perceived benefits and harms of treatment, effects of these on patients’ and partners’ 
lives, supportive care and follow up provided by the clinical team.  All answers were 
recorded directly onto the printed interview schedules. A majority of questions had 
pre-assigned response categories. Replies to the open-ended questions were written 
verbatim and then read back for confirmation of accuracy and understanding.  
 
Analysis 
The written material generated by open-ended questions was initially read and then 
independently coded into categories by both SC and LM with discrepancies resolved 
through discussion and if necessary adjudicated by VJ. All of the categorical data 
were summarised as counts and percentages and collated in tabular or graphic 
format, comparisons across patients and partners are presented where useful.  
 
Results      
193 men returned expression of interest forms , after further consideration 52 
declined participation and 8 were ineligible (not mCRPC=2, too ill=1, a systemic 
treatment not started=2, had been on treatment for >14 days=4). 132 men consented 
to the study of whom 33 together with their partners and 4 single men were 
interviewed.  
Table 1 summarises the demography for those interviewed and patients’ medical 
history, 22% (8/37) of whom were presenting with mCRPC for the first time, which 
was representative of the study sample as a whole (23%;30/132). The majority had 
bone metastases (60%, 22/37), a similar proportion to that of the whole study sample 
(62%, 82/132). The single men interviewed were on average older, none were 
University educated nor employed.  
 
Table 1 here 
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Views from the consultation about commencing treatment for mCRPC  
Table 2 presents a summary of the perceived worst symptom, language used by the 
doctor to convey the status of the cancer, and the decision time and perceived 
patient involvement at the consultation where the new treatment for mCRPC was 
discussed.  
 
Patients and partners views for the worst presenting prostate cancer symptom were 
only moderately congruent (Kappa value = 0.4). Pain was the worst presenting 
symptom from the perspective of a majority of the men, (though only one of the four 
single men), whilst partners more often reported the patient’s worst symptom as 
psychological distress and other urinary problems (i.e. incontinence).  
 
Few patients or partners recalled reference to mCRPC during the “new “treatment 
consultation to convey the disease status. Most recollected hearing the terms 
“advanced” or “progressive” prostate cancer used and/or the phrasing “the cancer 
has spread”, “the cancer is metastatic”, “treatment has stopped working”.  
 
Over a third said the treatment decision was made at the consultation when mCRPC 
was confirmed, others were given a longer time to decide. In most cases treatment 
decision making was viewed as a joint doctor-patient decision, with partners also 
involved.  
 
Table 2 here 
 
Figure 1 shows that most thought the aim of treatment was to delay cancer 
progression (>75%), and just over a third of partners, but fewer patients (15%) to 
extend life and around a third of both patients and partners to improve QoL.      
 
Figure 1 here 
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Experiences of information provision 
Table 3 gives an overview of the information leaflets and websites used by the 
patients. The majority of leaflets were from Macmillan and drug companies, which 
provided “very” or “fairly” useful information about SEs. However, a third of patients 
and 55% of partners had searched the internet for additional SE information. Few 
recalled website recommendations being made by the healthcare professionals and 
it was more likely for partners than patients to have visited websites.  
 
Table 3 here 
 
Pain management and treatment related side effects 
Table 4 shows at baseline 16/37 (43%) of men needed and had the opportunity to 
discuss pain management. One man did not find this very useful and a further three 
required a discussion, but this had not happened.  
By 3-months a third had discussed their pain recently with a healthcare professional; 
most (11/12, 92%) had found this very/fairly useful. However, nearly a fifth (7/37, 
19%) made comments attributing the pain to causes other than prostate cancer, for 
example:-  
 
A majority of men (16/37, 42%) reported fatigue as the worst SE at 3 months, and 
nearly a third had experienced some unexpected SEs, over 50% had sought help to 
manage them. 
 
Table 4 here 
 
 
“I think the pain in my hip could be rheumatic” (P14, 56yrs) 
 
“My pain in the lower back and shoulder are due to degeneration” (P1, 73yrs) 
 
“I put the backache down to gardening” (P33, 73yrs) 
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Support for patients and partners  
Figure 2 reveals inequitable provision of access to specialist nurse resources with 
nearly half of patients and partners reporting there was no specialist nurse available 
to talk to. 
 
Figure 2 here 
 
 
Around a third of patients (13/37, 35%) and partners (10/33, 30%) said they had 
received details of a local support group. Many of those not provided with this 
information said they were not interested (20/24, 83% patients; 20/23, 87% 
partners). About half (16/33, 49%) of the partnered men and three quarters (3/4, 
75%) of the single men accessed supportive services, the types of help are shown in 
figure 3. There was evidence of why some men were reluctant to, or had not used 
supportive services, for example:- 
 
 
 
Figure 3 here 
 
 
 
 
 
 
 “I prefer to keep things in the family, I get all my support from the family” (P4, 66yrs) 
 
“For me I think not wanting to have help from the hospice might be a male thing, 
wanting to keep going on your own” (P2, 68yrs) 
 
“He is a man he doesn't like to look weak and ask for help, he has had a couple of 
breakdowns at home, coping with the nausea & vomiting, pain and diarrhoea” (S6, 
68yrs)  
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Requests for improvements 
On reflection 11/37 (30%) of men and 12/33 (36%) of partners commented on how 
care might be improved for future patients. Suggestions for improved communication 
and information provision were prominent, for example:- 
 
 
There was also evident desire for improvements to be made to supportive care and 
the resource allocation that underpins this, comments such as:-  
 
 
“Very over worked staff, no opportunity to discuss my incontinence issues with a 
nurse” (P13, 69yrs) 
“I'm so tired, hot flushes, restless legs, feel exhausted, something to help all of these” 
(P9, 68yrs) 
“I feel particularly unsupported as a partner, we are a relatively young couple, I am 
worried about the future, I feel very much in the dark” (S2, 57yrs) 
“Help with psychological issues,… I am very worried about leaving my wife and son, 
…I feel there should be psychological support for them too” (P14, 56yrs) 
“More help and support with incontinence, I’m pretty much house bound now, I’m 
worried about having an accident while I’m out and about” (P37, 91yrs) 
“I think more contact with the nurse would give my husband more confidence. We feel 
at the clinic that we are on a bit of a conveyor belt and time is short with the doctor & 
nurse” (S6, 68yrs) 
“Consistency in information is vital, differing opinions from the doctor and nurse” (P28, 
76yrs) 
“Improvement of continuity of passing on information, across healthcare professionals 
and different hospitals, important points do sometimes seem to go missing” (P11, 
72yrs) 
“They (the healthcare professionals) don't seem to recommend any websites” (P12, 
70yrs) 
“Initially we struggled for information, only after the specialist referred us to the 
hospice did we get the support, information and help we really needed” (S3, 67yrs) 
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Discussion 
The interviews from EXTREQOL highlight the ongoing challenges facing mCRPC 
patients, their partners and HCPs in terms of finding treatment and care models to 
maximise survival and QoL.  
 
Three quarters of the patients in EXTREQOL had metastatic bone disease and pain 
was a commonly reported presenting symptom recognised by 43% of clinicians 
[Jenkins et al, 2018a]. This is important though not surprising and it fits with previous 
evidence showing that men with mCRPC experience poorer QoL and more pain than 
men at other stages of disease [Chambers et al, 2018]. Patients who managed to 
have a pain management discussion were in the main satisfied, however, some 
attributed their pain to their older age, or other conditions other than cancer e.g. 
arthritis, or an activity like gardening. Evidence from the Brief Pain Inventory data for 
the whole EXTREQOL study sample showed  only 39% (22/57) of those with 
moderate/severe pain experienced ≥70% pain relief from their analgesia, and  these 
proportions dropped to 37.5% (15/40) and 36.5% (15/41) at 3 & 6 months follow-up 
respectively [Jenkins et al, 2018b]. The overall picture from EXTREQOL and other 
studies is one of less than optimal pain management in this group of men.   A recent 
qualitative study of Australian men’s experiences of advanced prostate cancer 
documented similar findings on the influence men’s age and the expression of 
masculinities have on response to and coping with illness. They found a reluctance 
to seek help which the men ascribed to male values (being strong, capable, 
independent or stoic) and used avoidant coping, covering up or ignoring side-effects 
or a need for support [Chambers et al, 2018].      
 
Fatigue was a common SE of the mCRPC treatments and was difficult to manage by 
patients and staff as the EXTREQOL survey data showed. Doctors were less 
confident in being able to ameliorate fatigue compared to most specialist nurses 
(71%) who were confident [Jenkins et al, 2018a]. However, an imbalance in nurse 
support suggests many patients will miss out on such vital management discussions. 
In a report by the UK charity ORCHID (2012) a similar proportion, of around 50% of 
men, was highlighted as missing out on nurse support as found in the current study. 
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This coincides with an appeal from the prostate cancer workforce for more specialist 
nurses, which needs to double to equal the existing provision given to breast cancer 
patients [Prostate Cancer UK, 2014; Trevatt & Leary, 2010].    
 
The striking feature in regard to accessing supportive services was the relatively low 
level of usage and the expression of no interest in peer support groups from many 
men (20/37, 54%). Comments regarding their lack of engagement with services 
revealed a preferential reliance on spouses and family for primary support and 
masculinity influencing help seeking/acceptance. Another qualitative study revealed 
low emotional support-seeking and a similar preference for informal networks (i.e. 
partners, family & friends) [Ettridge et al, 2018].  Even men with localised prostate 
cancer are reluctant to seek help for their prostate-related concerns within the year 
following diagnosis (40%) and few had accessed psychological support [Hyde et al, 
2017]. This sits within a context where men’s general help-seeking behaviour is 
known to be low for both health and psychological problems [Yousaf, Grunfeld & 
Hunter, 2015]. The pattern is replicated in the general cancer setting where men 
compared to women are less likely to utilise support [Forsythe et al, 2013].  
 
In men generally and those with cancer, psychological barriers to seeking help have 
been identified as including: - restricted emotional expression, need for 
independence and control, gender role conflict and embarrassment [Yousaf, 
Grunfeld & Hunter, 2015; Fish et al, 2015]. Awareness of these factors is vital for 
supportive services to be designed to meet the needs of men with mCRPC and 
maximise their quality of life. It also flags up the interconnectedness of patients with 
partners and for their need to be involved and supported too. 
 
Without question the men and their partners were overwhelmingly grateful and 
complimentary of the treatment and care they had received. It was therefore in the 
spirit of improving things for future patients that requests for changes were 
articulated and broadly these were for improved communication and information 
provision and better supportive care underpinned by adequate resource allocation 
(specifically access to specialist nurse and palliative staff).  
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Conclusions 
More help to manage pain and other symptoms is required. Better specialist nurse 
access and earlier palliative care links would help to optimise symptom control, 
dedicated clinics maybe warranted.   
 
Limitations of the study 
The study sample lacked ethnic diversity and the experiences of black men in the 
UK, who are three times more likely to be diagnosed with prostate cancer than white 
men, have not been represented. Adoption of purposive sampling could help to 
address this in any future study.  
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Table 1: Demography and patients’ medical history  
 
Demography 
Partnered men 
(n=33) 
 
Single men  (n=4) 
Partners  
(n=33) 
Age(yrs): Mean, SD, min-max 70.8, 6.81, 56 - 89 80.5, 9.56, 71 - 91 67.6, 6.18, 54 - 
79 
University educated: n (%) 
 
12 (36) 0 9 (27) 
Employed: n (%) 6 (18) 0 9 (27) 
 
Medical history    
First presentation of mCRPC 
yes 
 
8  
 
0 
 
Site of metastasis: n (%) 
bone 
visceral 
both 
missing 
 
18 (55) 
8 (24) 
6 (18) 
1  
 
4 (100) 
- 
- 
- 
 
New treatment for mCRPC 
(baseline status): 
 
Started 
 
Awaiting 
 
Started 
 
Awaiting 
 
abiraterone (Zytiga)  
enzalutamide (Xtandi)  
docetaxel (Taxotere)  
radium-223 (Xofigo)  
cabazitaxel (Jevtana)  
steroid switch + abiraterone 
goserelin (Zoladex) 
docetaxel + AZD5363 
enzalutamide & radium-223 
5 
10 
5 
3 
2 
1 
- 
1 
- 
1 
1 
2 
1 
- 
- 
- 
- 
1 
- 
1 
- 
- 
- 
- 
1 
- 
- 
- 
1 
1 
- 
- 
- 
- 
- 
- 
 
Concurrent treatments: n (%) 
hormone injections  
bisphosphonate 
analgesia 
radiotherapy for bone mets 
 
31 (94) 
1 (3) 
16 (49) 
2 (6) 
 
3 (75) 
1 (25) 
2 (50) 
2 (50) 
 
Clinical trial offered: n (%) 5 (15) 1 (25)  
 
  
Authors’ submission copy accepted for publication by EJCC on 24.07.19. 
 
18 | P a g e  
 
Table 2: Worst symptom, disease status and treatment decision-making  
 Partnered 
men(n=33) 
n (%) 
Single men  
(n=4) 
n (%) 
Partners  
(n=33) 
n (%) 
Worst symptom:  
none 
pain 
fatigue 
psychological distress 
reduced physical function 
increased urinary frequency 
other urinary problem (incontinence) 
 
5 (15) 
15 (46) 
5 (15) 
1 (3) 
0 
4 (12) 
3 (9) 
 
0 
1 (25) 
1 (25) 
0 
1 (25) 
0 
1 (25) 
 
3 (9) 
11 (33) 
3 (9) 
3 (9) 
0 
4 (12) 
6 (18) 
Terms used to convey disease status:  
multiple responses possible 
 
none 
advanced prostate cancer 
progressive advanced prostate cancer 
metastatic castrate resistant prostate 
cancer (mCRPC) 
castrate resistant prostate cancer (CRPC) 
hormone resistant prostate cancer (HRPC) 
treatment has stopped working 
the Cancer has spread 
aggressive prostate cancer 
cancer is metastatic  
mCRPC/CRPC written in a summary letter 
 
 
 
 
2 (6) 
16 (49) 
7 (21) 
3 (9) 
0 
1 (3) 
8 (24) 
16 (49) 
4 (12) 
7 (21 
3 (9) 
 
 
 
 
2 (50) 
1 (25) 
1 (25) 
0 
0 
0 
1 (25) 
0 
0 
0 
0 
 
 
 
 
4 (13) 
17 (55) 
8 (26) 
4 (13) 
1 (3) 
1 (3) 
5 (16) 
13 (42) 
3 (10) 
5 (16) 
3 (10) 
Time available for treatment decision: 
decision made at consultation 
decision made at follow-up consultation 
however long needed 
 
11 (33) 
9 (27) 
13 (39) 
 
2 (50) 
0 
2 (50) 
 
9 (27) 
9 (27) 
15 (46) 
Treatment decision was made by: 
patient alone   
patient considering the doctor’s opinion  
doctor and patient decided together 
doctor considering the patient’s opinion   
doctor alone   
 
1 (3) 
8 (24) 
18 (55) 
3 (9) 
3 (9) 
 
1 (25) 
0 
2 (50) 
0 
1 (25) 
 
How involved are partners in the 
treatment decision-making process?: 
Very much 
Quite a bit 
A little 
Not at all (partner did not wish to be involved) 
 
 
25 (76) 
7 (21) 
0 
1 (3) 
 
 
 
 
 
20 (61) 
3 (9) 
4 (12) 
1 (3) 
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Table 3: Information provision  
 Partnered 
men(n=33) 
n (%) 
Single men  
(n=4) 
n (%) 
Partners  
(n=33) 
n (%) 
Type of written leaflets provided:  
multiple responses possible 
 
None 
Macmillan 
Cancer Research UK  
Prostate Cancer UK  
Hospital own  
Drug company own 
Other 
 
 
 
3 (9) 
15 (46) 
3 (9) 
0 
8 (24) 
16 (49) 
2 (6) 
 
 
 
1 (25) 
1 (25) 
0 
0 
0 
2 (50) 
0 
 
 
 
4 (12) 
13 (39) 
0 
1 (3) 
5 (15) 
15 (46) 
1 (3) 
Written side effect information provided:  
 
Yes, very useful  
Yes, fairly useful 
Yes, not very useful  
No written information received 
Don’t know 
 
 
21 (64) 
8 (24) 
0 
4 (12) 
 
 
2 (50) 
1 (25) 
0 
1 (25) 
 
 
 
20 (61) 
8 (24) 
0 
4 (12) 
1 (3) 
Side effects explicitly discussed:  
 
Yes 
No  
 
 
29 (88) 
4 (12) 
 
 
1 (25) 
3 (75) 
 
 
 
29 (88) 
4 (12) 
Looked side effects up on the internet:  
 
Yes 
 
 
11 (33) 
 
 
0 
 
 
18 (55) 
Websites recommended:  
multiple responses possible 
 
None 
Macmillan 
Cancer Research UK  
Prostate Cancer UK  
Hospital own  
Drug company own 
 
 
 
29 (88) 
4 (12) 
1 (3) 
1 (3) 
0 
0 
 
 
 
4 (100) 
0 
0 
0 
0 
0 
 
 
 
31 (93) 
1 (3) 
0 
1 (3) 
0 
0 
Websites utilised:  
multiple responses possible 
 
None  
Macmillan 
Cancer Research UK  
Prostate Cancer UK  
Hospital own  
Drug company own 
Other 
 
 
 
21 (64) 
4 (12) 
5 (15) 
5 (15) 
0 
0 
6 (18) 
 
 
 
3 (75) 
0 
1 (25) 
0 
0 
0 
0 
 
 
 
12 (36) 
7 (21) 
6 (18) 
4 (12) 
0 
0 
17 (51) 
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Table 4: Pain management and side effects experienced 
 
Patients, n=37 
 
Baseline 
n (%) 
 
3-months 
n (%) 
Pain discussed with a healthcare professional? 
 
Yes, very useful discussion 
Yes, fairly useful discussion 
Yes, not very useful discussion had 
No, discussion not required 
No, but wanted a discussion 
 
 
13 (35) 
2 (5) 
1 (3) 
18 (49) 
3 (8) 
 
 
8 (22) 
3 (8) 
1 (3) 
25 (67) 
0 
Worst side effect  
 
None 
Fatigue 
Nausea/vomiting 
Hot flushes 
Diarrhoea 
Dizziness 
Hypertension 
Poor kidney function 
Increased bone pain 
Indigestion 
 
 
 
 
 
8 (22) 
16 (42) 
3 (8) 
3 (8) 
2 (5) 
1 (3) 
1 (3) 
1 (3) 
1 (3) 
1 (3) 
Had unexpected side effect/s occurred? 
 
Yes 
 
 
 
 
 
10 (27) 
Asked for help with side effects? 
 
Yes 
 
 
 
 
 
20 (54) 
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Figure 1: Understanding of the aims of treatment  
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Figure 2: Patient and partner views of specialist nurse provision 
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Figure 3: Summary of the help men were accessing 
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